Spyre Therapeutics, Inc.
SYRE
$16.67
$0.784.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.20% | 42.64% | 38.60% | 27.01% | 31.76% |
| Total Depreciation and Amortization | -- | -- | -- | -100.00% | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.83% | -81.19% | -77.32% | -61.59% | -67.23% |
| Change in Net Operating Assets | 132.51% | -2,223.85% | 12.91% | -282.03% | -874.87% |
| Cash from Operations | 1.44% | -53.28% | -57.55% | -73.82% | -131.79% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -100.00% | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 84.41% | -5.87% | -215.71% | -248.09% | -795.89% |
| Cash from Investing | 86.36% | -7.48% | -225.93% | -268.76% | -751.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Common Stock | 167.26% | 168.48% | 187.07% | 83,477.24% | 498,938.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -100.00% | -42.56% | 20.84% | 20.84% |
| Repurchase of Preferred Stock | 98.28% | 97.19% | 97.19% | 97.19% | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 91.45% | 91.45% | 68.25% | -- | -- |
| Cash from Financing | -26.07% | -55.20% | 13.80% | 76.70% | 54.20% |
| Foreign Exchange rate Adjustments | 133.33% | -90.00% | -112.00% | -43.40% | -123.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.93% | -193.76% | -165.31% | -139.55% | -196.86% |